Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Serinus canaria feather extract, marketed under the brand name Canary Feathers by Greer Laboratories, is a non-standardized allergenic extract used for the diagnosis and treatment of allergies to canary feathers. As a biologic product, it is formulated as a solution for intradermal, percutaneous, or subcutaneous administration. The extract functions through allergen immunotherapy, which involves modulating the immune response by increasing antigen-specific IgG antibodies and decreasing specific IgE production. Due to the risk of severe anaphylactic reactions, it is intended for use by physicians experienced in allergen immunotherapy and emergency management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on serinus canaria feather extract.